OGS reports 18-month OGT 918 data

Researchers presented 18-month data from 18 Gaucher disease patients receiving Oxford Glycosciences' Vevesca ( OGT 918) oral N-butyldeoxynojirimycin glucosyltransferase inhibitor under an extension pr...